Finding your next opportunity shouldn’t require piecing together multiple databases, alerts and research tools.
Fundz combines its own funding and M&A intelligence with hiring, leadership and other business signals into one connected view of each company, ranks opportunities against your ideal customer profile, and delivers the evidence and verified contacts to act on. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for FS001 antibody-drug conjugate
Jul 11, 2024
Contract Type
agreement
ParisBiotechnology
Description
Ipsen and Foreseen Biotechnology have announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated antigen with the potential to unlock critical new treatments for people living with hard-to-treat forms of cancer.
Company Information
Company
Ipsen and Foreseen Biotechnology
Location
Paris, Ile-de-France, France
About
Ipsen is a global biopharmaceutical group focused on innovation and specialty care. Foreseen Biotechnology is a biotechnology company with a focus on discovering and developing innovative therapeutic products.
Predictive Intelligence
Strategic
ML-powered predictions for Ipsen and Foreseen Biotechnology's next move